Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Robert W. Scully net worth and biography

Robert Scully Biography and Net Worth

Director of Zoetis

Robert (Bob) W. Scully is currently a board member of Chubb Limited, Zoetis Inc., and KKR & Co.

Bob served as a Member of the Office of the Chairman of Morgan Stanley from 2007 to 2009 and was its Co-President responsible for Asset Management, Discover Credit Cards from 2006 to 2007. Prior to assuming the position of Co-President, he was Chairman of Global Capital Markets from 2004 to 2006, Vice Chairman of Investment Banking from 1999 to 2006, and Managing Director from 1996 to 2009. Previously, Bob was Managing Director at Lehman Brothers from 1993 to 1996, for Scully Brothers Foss & Wight from 1989 to 1993, Managing Director at Salomon Brothers in Investment Banking and Capital Markets from 1980 to 1989, where he became a Managing Director in 1984. He began his career in the banking industry with Chase Manhattan Bank.

Bob graduated in 1972 with a bachelor’s degree in psychology from Princeton University and holds an MBA from Harvard University.

Previously, Bob served on the boards of UBS Group AG, Bank of America Corporation and Dean's Advisors of Harvard Business School.

What is Robert W. Scully's net worth?: The estimated net worth of Robert W. Scully is at least $13.68 million as of February 12th, 2021. Mr. Scully owns 82,979 shares of Zoetis stock worth more than $13,678,258 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Scully may own. Learn More about Robert W. Scully's net worth.
How do I contact Robert W. Scully?: The corporate mailing address for Mr. Scully and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Robert W. Scully's contact information.
Has Robert W. Scully been buying or selling shares of Zoetis?: Robert W. Scully has not been actively trading shares of Zoetis over the course of the past ninety days. Most recently, on Friday, February 19th, Robert W. Scully bought 7,590 shares of Zoetis stock. The stock was acquired at an average cost of $164.68 per share, with a total value of $1,249,921.20. Learn More on Robert W. Scully's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO & Director), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 3,132 shares worth more than $547,983.01. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.2% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 4/18/2024.

Robert W. Scully Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/19/2021	Buy	7,590	$164.68	$1,249,921.20

Robert W. Scully Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $164.84

$163.53

$166.39

50 Day Range

MA: $178.52

$163.52

$194.45

2 Week Range

Now: $164.84

$144.80

$200.53

Volume

6,184,068 shs

Average Volume

2,552,173 shs

Market Capitalization

$74.37 billion

P/E Ratio

30.99

Dividend Yield

1.03%

Beta

0.89

First JFK… next Elon?

From Porter & Company | Ad